The Advances in Gastrointestinal Cancer Resource Centre Introduction

The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting-edge data to practising healthcare professionals. Our aim is to provide clinically relevant information, in order to enhance your ability to provide optimal care for your patients with gastrointestinal (GI) cancer. We offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, functions as an information hub for healthcare professionals

Advances in Gastrointestinal Cancer having focused initially on gastric cancer, has now expanded its scope to include all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in the management of GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.


ESMO 2016 Congress highlights


Article of the month

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial


Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al.
Lancet Oncol. 2016 Dec;17(12):1697-1708.
Selected and commented by Dr Lizzy Smyth
In this manuscript, Al Batran et al. present the results of the German FLOT4-AIO study in which 300 patients with patients with resectable gastric cancer were treated with either three cycles of neoadjuvant ECX/ECF (epirubicin, cisplatin and 5-fluorouracil or capecitabine) chemotherapy or four cycles of neoadjuvant FLOT (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) chemotherapy...

Latest Articles


Editors

Professor David Cunningham

Director of the Royal Marsden/Institute of Cancer Research NIHR Biomedical Research Centre and Director of Clinical Research

Professor Florian Lordick

University Hospital Leipzig, Leipzig, Germany

Dr Ian Chau

Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

Dr Elizabeth Smyth

Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK

Search this site

Search form

ECCO2017 Symposium

Joining a conversation on the treatment evolution in advanced GI malignancies: yesterday, today, and tomorrow

Official Sponsored Satellite Symposium at ECCO 2017: European Cancer Congress, 29 January 18:45 – 20:15

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Featured Content

New Book Content


This online Resource Centre has been sponsored by Lilly Oncology

Note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subject to an independent editorial review.

Share

Upcoming events